CD34+ selected donor cells

CD34+ selected donor cells are a purified population of hematopoietic stem and progenitor cells (HSPCs) derived from an allogeneic donor's peripheral blood or bone marrow. The production process typically utilizes immunomagnetic separation technology, such as the CliniMACS system, to selectively enrich for cells expressing the CD34 surface antigen while significantly depleting T-lymphocytes and other mature immune cells. This therapy is primarily indicated for patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) for hematologic malignancies, such as acute myeloid leukemia (AML). By drastically reducing the T-cell content of the graft, the therapy is designed to minimize the incidence and severity of Graft-versus-Host Disease (GvHD), a potentially fatal immune complication where donor T-cells attack recipient tissues, without requiring intensive pharmacological immunosuppression. The purified CD34+ cells retain the capacity to home to the bone marrow and differentiate into all lineages of the hematopoietic and immune systems, facilitating full engraftment and immune reconstitution.

Brand names

CliniMACS CD34 Reagent System

Other names

CD34-selected graftCD-34-selected graftCD 34-selected graftT-cell depleted donor cellsCD34-enriched hematopoietic stem cellsCD-34-enriched hematopoietic stem cellsCD 34-enriched hematopoietic stem cellsPurified allogeneic hematopoietic stem cellsCD34-selected hematopoietic progenitor cellsCD-34-selected hematopoietic progenitor cellsCD 34-selected hematopoietic progenitor cells